These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31807112)

  • 1. Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.
    Carrà G; Cartellà A; Maffeo B; Morotti A
    Blood Lymphat Cancer; 2019; 9():45-52. PubMed ID: 31807112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance.
    Singh VK; Coumar MS
    Mini Rev Med Chem; 2019; 19(4):333-345. PubMed ID: 30332954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment.
    Wieczorek A; Uharek L
    Biomark Insights; 2015; 10(Suppl 3):49-54. PubMed ID: 26917943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J; Hu J; Jin Z; Wan H
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of Chronic Myeloid Leukemia in Mice.
    Zhang H; Li S
    Methods Mol Biol; 2016; 1465():17-25. PubMed ID: 27581135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.
    Liao Y; Liu N; Xia X; Guo Z; Li Y; Jiang L; Zhou R; Tang D; Huang H; Liu J
    Cell Discov; 2019; 5():24. PubMed ID: 31044085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
    Marfe G; Di Stefano C
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):58-68. PubMed ID: 19663771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.
    Shah K; Parikh S; Rawal R
    Asian Pac J Cancer Prev; 2016; 17(7):3025-33. PubMed ID: 27509925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia stem cells: the root of chronic myeloid leukemia.
    Zhou H; Xu R
    Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
    Alikian M; Gale RP; Apperley JF; Foroni L
    Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
    Massaro F; Colafigli G; Molica M; Breccia M
    Expert Rev Hematol; 2018 Apr; 11(4):301-306. PubMed ID: 29522367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.